Navigation Links
Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Date:8/29/2007

EXPANDED CLINICAL PROGRAM SUPPORTED BY PROMISING RESULTS FROM COMPLETED

TRIAL

TORONTO, Aug. 29 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced completion of a proof of concept clinical trial in Acute Myeloid Leukemia (AML), and expansion of its GTI-2040 development program in this indication, with initiation of a more advanced Phase II clinical trial with GTI-2040 and high dose Ara-C (HiDAC) in refractory and relapsed AML.

The advanced Phase II clinical trial, which is now underway, includes both an efficacy study and a novel additional study to measure intracellular target activities and pharmacological synergies between the two agents. In the first stage of the 60 patient trial, the pharmacologic and target related activity of GTI-2040 and HiDAC will be evaluated in two groups, to determine the contribution of each agent alone and in combination. The second stage of the trial will provide efficacy evaluation in a larger patient population. Lorus expects the clinical trial to be completed by the end of 2008.

The decision by Lorus to advance clinical development of GTI-2040 is based on the encouraging results from our recently completed proof of concept study of GTI-2040 in combination with HiDAC in patients with refractory and relapsed AML. This clinical trial demonstrated safety and appropriate dosing of the combination regimen and showed promising clinical responses in patients under 60 years of age. Moreover, the clinical responses correlated with downregulation of R2, the cellular target of GTI-2040, and were further supported by demonstration of intracellular GTI-2040 in circulating and bone marrow leukemic cells. Complete results from the clinical trial are expected to be presented by the investigators in
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
2. Quintessence Biosciences advances cancer drug
3. Healthcare slow to adopt genetic advances
4. Wireless advances in Madison, heats up in Waukesha
5. GE Healthcares CT Scanner advances coronary imaging
6. Cancer treatment advances as trials show no harm to mice
7. New CT scanner by GE Healthcare advances imaging technology
8. Small wonders: Intersection of biotech and nanotech will produce big advances
9. Standards Needed for Advances in Healthcare Technology
10. BioRobot MDx standardize your automated protocols in clinical laboratories
11. What patients want: A story of choice, clinical trials & evidence-based medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... in water with ultrasound and they,ll spin around their ... yet knows exactly. But researchers at the National Institute ... it,s fast. At up to 150,000 revolutions per minute, ... object submerged in liquid ever reported. , The discovery ... that they could be used not only for moving ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Automated cell ... and maintenance of cell culture. They allow production of ... needs of researchers in drug discovery and industries and ... in mAb production, iPSC research, cryobanking, cell-based assays, and ... contamination risk. , Analysts forecast the Global Cell ...
(Date:7/22/2014)... (NASDAQ: NEOG ) announced today that revenues ... increased 19% from the previous year to $247,405,000. Fiscal ... year,s $27,190,000. Adjusted for a 3-for-2 stock split effective ... year were $0.76, compared to $0.75 a year ago. ... year established new all-time highs for the 32-year-old company. ...
(Date:7/22/2014)... PITTSBURGH , July 22, 2014 ... maker of MD-Cu 29 antimicrobial copper announces Pullman ... to the first EPA-registered antimicrobial solid touch surface, at ... than 99.9% of MRSA, E-coli and other bacteria within 2 ... hospital in protecting against bacteria and infectious diseases in ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... Mich., Sept. 10 The primary objective of ... the delivery of,biomedical advances to the marketplace. ... at Boston University on,Friday, September 7th with noted ... Presidents of both Boston,University and Fraunhofer Gesellschaft. ...
... by prominent,Board members Robert Windom, M.D. and Steven ... with inventor Dr. Budimir Drakulic -,have this day ... approved, ambulatory 12-lead ECG cardiovascular,monitor. In private ... ten,days, the trio of cardiovascular experts and Signalife,s ...
... (Amex: PTN ) today announced it has ... melanocortin agonist drug,candidate for the treatment of male ... King Pharmaceuticals Inc. (NYSE: KG ). ... development,and marketing agreement on bremelanotide, with King exercising ...
Cached Biology Technology:'Alliance for Medical Devices, Instrumentation and Diagnostics' formed between Fraunhofer Center for Manufacturing Innovation and Boston University 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 3Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 2Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 3
(Date:7/22/2014)... In contrast to their negative reputation as disease ... and evolutionary functions that help to shape the ... new report by the American Academy of Microbiology. ... influence all life forms on the planet, from ... and driving major speciation events," states Marilyn Roossinck ...
(Date:7/22/2014)... NY -- Stem cells offer much promise for treating ... stem cell survival is poor, limiting their effectiveness. New ... survival and optimize their therapeutic function after transplantation, as ... Access , a peer-reviewed journal from Mary Ann Liebert, ... BioResearch Open Access website . ...
(Date:7/22/2014)... hear that drinking milk helps make their bones strong or that ... the idea that if something is good for us, it must ... Journal of Consumer Research , when children hear about the benefits ... predicted that when food is presented to children as making them ... learning how to read or count, they would conclude the food ...
Breaking Biology News(10 mins):Report on viruses looks beyond disease 2
... academic, government and industry researchers has completed a first draft ... important first step in accelerating the pace of research on ... that face cassava farmers around the world. Cassava is ... for more than 750 million people each day. Although it ...
... 9 Genencor, a division of Danisco, has ... American Institute of Chemical Engineers (AIChE) for its ... Robert Davis, Chair of the AIChE Awards committee, ... Marketing Director, Biomass Enzymes and Accellerase® Product Manager, ...
... A chemical culprit responsible for the rapid, mysterious death ... found by collaborating scientists at Rutgers University and the ... may hold unexpected promise in cancer research. The ... in a virus that has been attacking and killing ...
Cached Biology News:Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4
1M stock solution (238mg/ml)...
...
Request Info...
... peptide derived from the C-terminal region catalytic ... C zeta isoform (PKCzeta). Specificity: Reacts ... Recognizes PKCzeta and PKMzeta (PKCzeta II) ... Reactivity: Mouse Rat (positive controls: mouse and ...
Biology Products: